Reviews/Giant Cell Arteritis/Large-vessel ultrasound adds sensitivity
Imaging · GCA-IMG-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Across separate patient groups, scanning the large arteries of the chest and shoulders in addition to the temple arteries let ultrasound pick up more people who actually had giant cell arteritis. In one group the detection rate rose from 83.9% to 96.6% [1], and in another, judged against PET/CT scans, it rose from 71% to 97% [3]. A third study found that a wider scan uncovered large-vessel involvement in far more patients and would have stopped a small number of diagnoses being missed [4]. The main reason the panel did not treat this as settled is that in two studies the large-vessel findings helped define who counted as a case in the first place, so some of the apparent improvement is built into how the diagnosis was made. The technique also needs skilled operators and good equipment, and widening the scan can flag harmless age-related artery thickening.
Two direct cohort studies show a large rise in diagnostic sensitivity when large-vessel ultrasound is added to temporal-artery ultrasound: 83.9% to 96.6% in [1], with specificity unchanged at 97.3%, and 71% to 97% in [3] against an FDG PET/CT reference. [4] found extended A2-ultrasound detected large-vessel involvement in 69.9% of patients versus 42.1% with limited ultrasound (P < 0.001), with 3.8% who would have been missed on limited ultrasound alone. [2] and [6] confirm ultrasound reliably detects extracranial large-vessel disease, strongest in the axillary and subclavian arteries, with [2] reporting an overall Doppler sensitivity of 80%. The direction of the effect is uniform across these independent European cohorts. The contested point: The division is over how much of the measured sensitivity gain is real versus definitional: in [1] and [3] the reference GCA diagnosis itself incorporated large-vessel findings, so adding large-vessel ultrasound can mechanically reclassify isolated large-vessel cases as positive. [3] partly offsets this by using a PET/CT reference, but the magnitude of the gain over a fully independent standard remains uncertain.
All 9 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Giant Cell Arteritis, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Incorporation bias: in [1] and [3] the reference GCA diagnosis itself incorporated large-vessel findings, so adding LV US mechanically reclassifies isolated-LV cases as positive, inflating the apparent sensitivity gain beyond any true accuracy improvement. [3] partly mitigates this with a PET/CT reference.
[1] is a single-centre retrospective observational cohort, carrying selection and verification bias.
Where it remains uncertain. In [1] and [3] the reference diagnosis incorporated large-vessel findings, so part of the gain is definitional rather than a true accuracy improvement, and [1] is retrospective.
Aleatory
Isolated large-vessel involvement rests on 11 patients (12.6%) in [1] and the otherwise-missed fraction on 5 patients (3.8%) in [4], so the incremental yield is estimated from few events.
Epistemic
[4] states extended A2-ultrasound requires high expertise and high-end equipment, so whether the gain transfers to non-expert fast-track clinics is not established by the corpus.
The load-bearing papers from a corpus of 9, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary direct evidence: quantified sensitivity gain from adding LV to temporal CDUS with specificity preserved.
“Adding a CDUS examination of LV to TA increased sensitivity (from 83.9 to 96.6%) and the negative predictive value (from 88.5 to 98.2%) for diagnosis of GCA.”
Panel auditInternal validity: medium · scope of inference: Ultrasound diagnostic accuracy in patients with suspected GCA at a single centre using the halo sign.Key limitations: retrospective · single-centre · clinical final diagnosis as reference · no p value for sensitivity gain
Prospective confirmation against an FDG-PET/CT reference standard, strengthening independence from incorporation bias.
“Adding LV US to temporal assessment increased sensitivity from 71% to 97% (all GCA patients).”
Panel auditInternal validity: high · scope of inference: Patients aged ≥50 with raised inflammatory markers and potential GCA symptoms, using axillary ultrasound with PET/CT reference.Key limitations: single reference centre · no p value for sensitivity gain · axillary-focused large-vessel US
Shows extended large-vessel scanning captures cases that limited examination misses.
“Five patients (3.8%) would have been missed as having GCA if only limited ultrasound was performed.”
Panel auditInternal validity: medium · scope of inference: Newly diagnosed GCA patients, comparing extent of large-vessel ultrasound examination; requires high expertise and high-end equipment.Key limitations: all patients ultrasound-positive at entry · operator-dependent · no p value for the missed-diagnosis figure
Establishes that ultrasound reliably detects extracranial large-vessel disease, the mechanism underlying the sensitivity gain.
“DS detected 24 out of 30 cases of LVV (overall sensitivity 80.0%).”
Panel auditInternal validity: medium · scope of inference: Doppler sonography accuracy by arterial site in extracranial, non-temporal large-vessel vasculitis.Key limitations: retrospective · small sample · extracranial-only population · no additive-sensitivity comparison
4 of 9 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The direction and magnitude of the sensitivity gain are consistent across independent cohorts, but incorporation bias and retrospective elements partly inflate the effect, warranting a Likely rather than Established tier.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Reference standard independent of ultrasound. In [1] and [3] large-vessel findings informed the GCA diagnosis, so the measured gain is partly definitional; isolating true accuracy needs a reference that does not include ultrasound. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Prospective cohort of suspected GCA in which the final diagnosis is set by PET/CT and clinical follow-up blinded to ultrasound, with added large-vessel ultrasound sensitivity measured against it.
Open question: How large is the added sensitivity of large-vessel ultrasound when the reference diagnosis does not itself incorporate large-vessel ultrasound findings? Why it is still open: The gains in [1] and [3] are measured against references that included large-vessel findings, so incorporation bias cannot be separated from true accuracy; [3]'s PET/CT reference only partly mitigates this.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19